Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00229-19. Print 2019 Aug.
Treatment of bacterial infections is increasingly challenged by resistance to currently available antibacterial agents. Not only are such agents less likely to be active today than they were in the past, but their very use has selected for and continues to select for further resistance. Additional strategies for the management of bacterial illnesses must be identified. In this review, bacteriophage-based therapies are presented as one promising approach. In anticipation of their potential expansion into clinical medicine, clinical microbiologists may wish to acquaint themselves with bacteriophages and their antibacterial components and, specifically, with methods for testing them. Here, we reviewed the literature spanning January 2007 to March 2019 on bacteriophage and phage-encoded protein therapies of relevance to clinical microbiology.
治疗细菌感染的难度正日益增加,因为当前可用的抗菌药物已出现耐药性。这些药物不仅现今的疗效不如过去,而且其使用本身就会选择并继续选择产生更多耐药性。我们必须确定其他管理细菌感染的策略。在这篇综述中,噬菌体疗法被认为是一种很有前途的方法。为了做好这些噬菌体在临床上广泛应用的准备,临床微生物学家可能希望熟悉噬菌体及其抗菌成分,特别是噬菌体的检测方法。在此,我们回顾了 2007 年 1 月至 2019 年 3 月期间与临床微生物学相关的噬菌体和噬菌体编码蛋白治疗的文献。